The mechanism of MPTP resistance in synuclein null mice.

Columbia University Health Sciences, New York NY

Investigators

Linked publications & trials

Abstract

DESCRIPTION (provided by applicant): My long-held career goal is to investigate questions of importance to both patient care and fundamental biology. During medical training, I developed a strong interest the basic pathogenic mechanisms of Parkinson's disease (PD), an illness characterized by degeneration of substantia nigra dopamine (DA) neurons and cytoplasmic aggregates of alpha-synuclein (SYN). I came to appreciate the power of genetically modified animals as tools to explore basic aspects of disease pathogenesis, and developed expertise in the generation of such animals. However, I now need to acquire skills necessary to assess the consequences of PD-related mutations on cellular and behavioral aspects of dopaminergic function in these animals. To accomplish this goal, I have developed collaborations with experts in PD research, and will pursue the proposed work within the integrated PD research group at Columbia University. Rarely, PD may be caused by missense mutations in SYN. However, normal SYN function and the mechanism by which pathogenic mutations disrupt SYN biology and lead to PD are poorly understood. MPTP-induced degeneration of DA neurons is a commonly studied model of PD. We find that SYN null mice display striking resistance to MPTP-induced degeneration of DA neurons, and this resistance appears to result from an inability of the toxin to access and inhibit its target, mitochondrial complex I. The goal of this research plan is to exploit this robust phenotype of SYN null mice to gain insight into the normal function of SYN, and explore how this function is altered by PD-causing mutations. In Aim 1 we will measure whether known concomitants of complex I inhibition (increased lactate and reactive oxygen species; decreased ATP) are also impaired in SYN null mice, and characterize processes that control access of the toxin to complex I (vesicular and monoamine transporter function). In Aim 2 we will further explore whether altered synaptic function underlies the MTPT resistance of SYN null mice by testing whether they are selectively resistant to toxins that traffic through the synapse. In Aim 3, by restoring wild type or mutant SYN to specific neuronal populations of SYN null mice, we will test whether the MPTP resistance is a cell autonomous phenomenon and whether pathogenic SYN mutations modify an aspect of its function involved in effecting MPTP-induced neurodegeneration. This proposal exemplifies the type of clinically related fundamental neurobiological research I plan to pursue during my career.